Because of the inaccuracy and low efficiencies of traditional treatment, such as surgery, chemotherapy, and radiotherapy, in recent years, RDC (Radionuclide Drug Conjugate), with targeted diagnosis and imaging, has been widely noticed and studied in recent years.

The targeting biomolecules in RDC could be antibodies, small molecules, and peptides, in which antibodies are most commonly used, also name RAC (Radionuclide Antibody Conjugate).

Rdcthera, adapting the advanced antibody discovery technology, is professional at antibody discovery, screening, and synthesis.

Web: https://www.rdcthera.com/a...

Radionuclide Drug Conjugates (RDCs) represent a promising frontier in cancer therapy, offering a targeted approach to eliminate cancer cells while minimizing damage to healthy tissue. One exciting avenue of research involves RDCs targeting the ADRB1 gene, which codes for the Adrenergic Receptor Beta 1 protein. This article explores the potential of RDCs in the context of ADRB1, shedding light on their mechanisms, applications, and the implications for cancer treatment.
For more information, please visit at: https://www.rdcthera.com/r...

The small molecule, which is widely used in cancer therapy, has been recently introduced into RDC (Radionuclide Drug Conjugate) development. The combination of molecular targeted therapy with radiotherapy is a creative concept to improve cancer therapy efficacy and reduce damage to healthy cells in patients.

Rdcthera offers a professional small molecule design and synthesis service with high quality for RDC development projects.
https://www.rdcthera.com/s...